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S U M M A R Y
Objectives: To investigate the dynamic development of the antimicrobial resistance of Campylobacter
jejuni isolated from human diarrhea in Beijing, China, between 1994 and 2010, and to further analyze the
molecular mechanisms of erythromycin-resistant strains.
Methods: Susceptibility tests were performed on 203 non-duplicate clinical C. jejuni strains against eight
common antibiotics using the standard agar dilution method. The molecular determinants were further
studied in the erythromycin (ERY) non-susceptible strains. The analysis focused on the 23S rRNA gene,
the rplD and rplV ribosomal genes, the ermB gene, and the regulatory region of the CmeABC efﬂux pump.
Results: The rates of resistance of C. jejuni to ciproﬂoxacin (CIP), nalidixic acid (NAL), doxycycline (DOX),
tetracycline (TET), ﬂorfenicol (FFC), and chloramphenicol (CHL) increased signiﬁcantly over the period
studied (all p < 0.05). Similarly, the proportions of resistant patterns (CIP–NAL–DOX–TET, CIP–NAL–
DOX–TET–FFC, and CIP–NAL–DOX–TET–CHL) increased remarkably. In this study, 4.4% (9/203) of C.
jejuni strains were ERY non-susceptible. The A2075G mutation in the 23S rRNA was found in all of the
resistant strains except cj8091, which harbored the ermB gene. Interestingly, the ermB gene was also
detected in intermediately resistant isolates, and the earliest ermB-positive strain cj94473 was derived
in 1994. Moreover, none of the ribosomal rplD or rplV genes harbored mutations that have been
described to confer resistance to macrolides. Different mutations affecting the regulatory region of the
CmeABC efﬂux pump were also found.
Conclusions: This is the ﬁrst comprehensive study on the recent trend in antimicrobial resistance and the
molecular mechanisms of macrolide resistance in clinical C. jejuni strains isolated in China. More
stringent monitoring and regulation of human and animal antimicrobial use are warranted.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Campylobacter jejuni, a food-borne zoonotic pathogen, is
considered one of the most common causes of bacterial
gastroenteritis worldwide, especially in developed countries.1
Few cases of C. jejuni infection have been reported in developing* Corresponding author. Fax: +86 10 66551680.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).countries, and these cases have been characterized by marked
seasonality and localized outbreaks.2 The transmission of C. jejuni
to humans occurs largely through the consumption of contami-
nated food and animal products, especially poultry.3 The common
symptoms of campylobacteriosis are watery or bloody diarrhea,
abdominal pain, fever, and nausea.4,5 Additionally, Guillain–Barre´
syndrome (GBS) is a severe sequela that mainly occurs after C.
jejuni infection and is mediated by an autoimmune demyelinating
polyneuropathy of the peripheral nervous system.4
Although C. jejuni infections are typically self-limiting and
usually resolve within a few days without antibiotic therapy,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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acute diarrhea and immunocompromised or pregnant patients,
particularly in developing countries. Macrolides and ﬂuoroquino-
lones, such as erythromycin and ciproﬂoxacin, are recommended
as the ﬁrst and alternative choices, respectively, in the clinical
treatment of campylobacteriosis. However, rapidly increasing
frequencies of C. jejuni strains that are resistant to these antibiotics
and isolated from various sources (e.g., humans, poultry, or food
production) have been reported in numerous studies,6–8 which
could compromise future treatment.
Hence, the aim of this study was to describe the dynamic
development of the antimicrobial resistance of C. jejuni isolated
from human diarrhea between 1994 and 2010 in Beijing, China.
The molecular mechanisms of resistance to macrolides were
further analyzed.
2. Materials and methods
2.1. Bacterial isolates and culture conditions
A total of 203 non-duplicate strains were isolated from stool
samples of diarrhea patients (n = 203) between January 1994 and
December 2010 in the Department of Infectious Diseases, Peking
University First Hospital, Beijing, China. All patients included in the
study were over 14 years of age. The isolates were grown on Skirrow’s
medium (Columbia agar base supplemented with 5% sheep blood at
37 8C for 48 h in a microaerobic environment containing 5% O2, 10%
CO2, and 85% N2). The identiﬁcation of C. jejuni was performed using
multiple PCR, as reported previously.9 All strains were preserved in
Mueller–Hinton (MH) broth with 20% glycerol at 80 8C.
2.2. Antimicrobial susceptibility testing
The minimum inhibitory concentrations (MICs) of eight anti-
biotics in the C. jejuni isolates were measured using the standard
agar dilution method, according to the Clinical and Laboratory
Standards Institute guidelines.10 Mueller–Hinton agar plates were
supplemented with 5% sheep blood and incubated for 48 h at 37 8C.
C. jejuni ATCC 33560 was used as a quality control strain for
susceptibility testing in the antimicrobial susceptibility determina-
tions. The C. jejuni isolates were considered resistant to chloram-
phenicol (CHL), ciproﬂoxacin (CIP), nalidixic acid (NAL), and
tetracycline (TET) at MICs of 32, 4, 64, and 16 mg/ml,
respectively.10,11 For gentamicin (GEN), ﬂorfenicol (FFC), and
doxycycline (DOX), the isolates with MICs 8 mg/ml were consid-
ered resistant.11 Additionally, the MIC breakpoints for erythromycin
(ERY) were those deﬁned by the CLSI, as follows: susceptible, 8 mg/
ml; intermediate, 8–32 mg/ml; and resistant, 32 mg/ml.12 StrainsTable 1
Primers used in this study
Gene Primer Sequence (50!30) 
23S rRNA F1-campy-23S AAGAGGATGTATAGGGTGT
R1-campy-23S AACGATTTCCAACCGTTCTG
rplD L4 Fwd GTAGTTAAAGGTGCAGTAC
L4 Rev GCGAAGTTTGAATAACTAC
rplV CJ20 TCCGGTTTATATTACTGAA 
CJ21 CTTTAGTTGGAAACCATCTT
ermB Erm-F CAGGTAAAGGGCATTTAAC
Erm-R CATCTGTGGTATGGCGGGT
IR regiona CmejejuniF TTGCCAATTGGATAGAAAA
CmejejuniR TCGTATTCCTTTTGAGAGAT
CmeR-F TAGAAAAGTATATTTGTATA
CmeR-R CGCCACTAACTTGAGGCTTT
a IR region, a CmeR–CmeA intergenic region upstream of the CmeA gene.
b The primers for the ermB gene were designed on the basis of GenBank accession nwith MICs 256 mg/ml were considered to have high-level
resistance to ERY.
2.3. PCR ampliﬁcation of genes and sequence analysis
Genomic DNA was extracted using the QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany) following the manufacturer’s instruc-
tions. The 23S rRNA, the ribosomal protein coding genes rplD and
rplV, the regulatory region of CmeABC (between CmeR and CmeA),
and the ermB gene were detected in erythromycin non-susceptible
(i.e., intermediate and resistant) C. jejuni strains (MIC 16 mg/ml)
and susceptible strains. The genomic targets and primer sets used
are listed in Table 1.13–17
The PCR products were puriﬁed and then sequenced by the
Biomed Corporation (China, Beijing), and the sequences were
analyzed to identify mutations using the BLAST program of the
GenBank sequence database.
2.4. Statistical analysis
The statistical analysis was performed using GraphPad Prism
5.0 software. The Chi-square test and Fisher’s exact two-tailed test
were used to compare differences in the ratios of resistance
between the different periods of time. The rates of resistance of the
isolates and their 95% conﬁdence intervals (95% CIs) were
calculated overall. Differences were considered signiﬁcant at p-
values of <0.05.
3. Results
3.1. Changes in the antimicrobial susceptibility of C. jejuni
A total of 203 non-duplicate C. jejuni isolates obtained at Peking
University First Hospital from 1994 to 2010 were analyzed in this
study. By time period, the numbers of isolates obtained were 18 in
1994–1996, 25 in 1997–1999, 63 in 2000–2002, 27 in 2003–2005,
41 in 2006–2008, and 29 in 2009–2010. The frequencies of
resistance of C. jejuni to eight common antimicrobial agents are
summarized in Table 2. The data revealed a continuous increase in
antimicrobial resistance to CIP, NAL, DOX, TET, FFC, and CHL during
the period 1994–2010, and all of the changes were statistically
signiﬁcant (50–100%, p < 0.001; 50–100%, p < 0.0001; 66.7–100%,
p < 0.0094; 72–100%, p < 0.0006; 12–62%, p < 0.005; 5.6–34.5%,
p < 0.05, respectively). In contrast, the total proportions of isolates
that were resistant to ERY and GEN were relatively low, and the
changes in the resistance to these antibiotics remained non-
signiﬁcant (p = 0.5797 and 0.2621, respectively).
The proportions of the C. jejuni isolates that were resistant to at
least four of the antimicrobial agents used in the study were alsoAnnealing temperature (8C) Reference
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Table 2
Rates of antibiotic resistance in clinical Campylobacter jejuni isolates between 1994 and 2010
Antibioticsa Rates of resistant isolates % (95% CI) Total %
(95% CI)
(n = 203)
p-Value
1994–1996
(n = 18)
1997–1999
(n = 25)
2000–2002
(n = 63)
2003–2005
(n = 27)
2006–2008
(n = 41)
2009–2010
(n = 29)
CIP 50.0 (26.0–73.9) 60.0 (38.7–78.9) 93.7 (84.5–98.2) 100 (87.2–100) 95.1 (83.5–99.4) 93.1 (77.2–99.1) 86.7 (81.2–91.0) <0.0001
NAL 50.0 (26.0–73.9) 60.0 (38.7–78.9) 93.7 (84.5–98.2) 100 (87.2–100) 95.1 (83.5–99.4) 93.1 (77.2–99.1) 86.7 (81.2–91.0) <0.0001
DOX 66.7 (41.0–87.0) 56.0 (34.9–75.6) 84.1 (72.7–92.1) 100 (87.2–100) 78.0 (62.4–89.4) 89.7 (72.6–97.8) 80.8 (74.7–86.0) 0.0094
TET 77.8 (52.4–93.6) 72.0 (50.6–78.9) 95.2 (86.7–99.0) 100 (87.2–100) 92.7 (80.1–98.5) 100 (88.1–100) 91.6 (86.9–95.0) 0.0006
GEN 0 (0–18.5) 0 (0–13.7) 12.7 (5.6–23.5) 0 (0–12.8) 12.2 (4.1–26.2) 6.9 (0.8–22.8) 7.4 (4.2–11.9) 0.2825
CHL 5.6 (1.0–27.3) 0 (0–13.7) 15.9 (7.9–27.3) 0 (0–12.8) 9.8 (2.7–23.1) 34.5 (17.9–54.3) 12.3 (8.1–17.6) 0.0059
FFC 22.2 (6.4–47.6) 12.0 (2.5–31.2) 36.5 (24.7–49.6) 18.5 (6.3–38.1) 26.8 (14.2–42.9) 62.0 (42.3–79.3) 31.5 (25.2–38.4) 0.0051
ERY 0 (0–18.5) 0 (0–13.7) 1.6 (0–8.5) 0 (0–12.8) 7.3 (1.5–19.9) 0 (0–11.9) 2.0 (0.05–5.0) 0.2621
CIP–NAL–DOX–TET 33.3 (13.3–59.0) 44.0 (24.4–65.0) 81.0 (69.1–89.8) 100 (87.2–100) 78.0 (62.4–89.4) 82.8 (64.2–94.1) 74.4 (68.3–80.7) <0.0001
FFC–CIP–NAL–
DOX–TET
11.1 (1.4–34.7) 12 (2.5–31.2) 31.7 (20.6–44.7) 18.5 (6.3–38.1) 26.8 (14.2–42.9) 62.1 (42.3–79.3) 29.0 (22.9–35.8) 0.0003
CHL–FFC–CIP–NAL–
DOX–TET
0 (0–18.5) 0 (0–13.7) 11.1 (4.6–21.6) 0 (0–12.8) 9.8 (2.7–23.1) 31.0 (15.3–50.8) 9.9 (6.1–14.8) 0.0004
GEN–FFC–CIP–NAL–
DOX–TET
0 (0–18.5) 0 (0–13.7) 9.5 (3.6–19.6) 0 (0–12.8) 9.8 (2.7–23.1) 6.9 (0.8–22.8) 5.9 (3.1–10.1) 0.2194
95% CI, 95% conﬁdence interval.
a CIP, ciproﬂoxacin; NAL, nalidixic acid; DOX, doxycycline; TET, tetracycline; GEN, gentamicin; CHL, chloramphenicol; FFC, ﬂorfenicol; ERY, erythromycin.
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CIP–NAL–DOX–TET, FFC–CIP–NAL–DOX–TET, and CHL–FFC–CIP–
NAL–DOX–TET increased signiﬁcantly over the 17-year period
(p < 0.0001, p = 0.0003, and p = 0.0004, respectively). In contrast, a
trend towards an increase in the susceptibility of CHL–FFC–CIP–
NAL–DOX–TET was not signiﬁcant (p = 0.2194).
3.2. Mechanisms of macrolide resistance
To investigate the molecular mechanisms of the ERY-resistant
isolates, the characteristics of macrolide resistance associated with
the genes was analyzed in four resistant isolates (cj8091, cj8036,
cj2000, and cj8083), ﬁve intermediate isolates (cj94473, cj6033,
cj2260, cj5082, and cj99117) and two susceptible isolates (cj6073
and cj99166). As illustrated in Table 3, multiple mutations were
observed in the target genes, including 23S rRNA, rplD, rplV, and the
regulatory region of CmeABC; furthermore, the presence of the
recently reported macrolide resistance-related ribosomal RNA
methylase gene ermB was noted.18
3.2.1. Analysis of the 23S rRNA gene
The A2075G mutation in the 23S rRNA gene, which is
responsible for high-level resistance to ERY (MIC 256 mg/ml),
was detected in all of the resistant strains except cj8091 (Table 3).Table 3
Characteristics of macrolide-resistant genes in Campylobacter jejunia
Strain/year ERY MIC
(mg/ml)
Mutation in
23S rRNA gene
ermBb Ribosomal protein polymorph
L4 Mutation L22 Mutatio
cj8091/2008 512 wt + V196A I65V A74G S
cj8036/2008 512 A2075G + V196A I65V A74G S
cj2000/2000 256 A2075G  V196A I65V A74G S
cj7083/2007 512 A2075G  V196A I65V A74G A
cj94473/1994 16 wt + N95S V196A Q24R S109A
cj6033/2006 16 wt + V196A I65V A74G S
cj2260/2002 16 wt  V196A I65V A74G S
cj5082/2005 16 wt  A114V V196A I65V A103V
cj99117/1999 16 wt  A114V V196A I65V A103V
cj6073/2006 2 wt  V196A I65V A103V
cj99166/1999 0.5 wt  WT WT 
ERY, erythromycin; MIC, minimum inhibitory concentration; V, Val; A, Ala; N, Asn; S, 
a Based on corresponding sequences of Campylobacter jejuni NCTC 11168 (GenBank 
b +/, indicates whether or not the target genes were detected.
c *, Nucleotide A deletion in the second half-site of the IR.3.2.2. Analysis of the L4 and L22 ribosomal protein genes
Regarding the L4 ribosomal protein gene, none of the high-level
ERY-resistant strains harbored the described mutations Gly-to-Asp/
Val (G57D/V) and/or Gly-to-Asp (G74D) that confer resistance to
macrolides. However, three different mutations in the L4 ribosomal
protein gene, including Val-to-Ala (V196A), Asn-to-Ser (N95S), and
Ala-to-Val (A114 V), were identiﬁed in this study (Table 3).
Regarding the L22 ribosomal protein gene, eight non-synonymous
mutations and two deletions (delThr–Thr–Thr–Lys–Ala at positions
120–124 and delThr at position 130) were detected.
3.2.3. cmeR–cmeA intergenic region analysis
The IR region was located either from 46 to 31 (consensus
sequence: TGTAATAAAAATTACA) or from 50 to 35 (consensus
sequence: TGTAATAAATATTACA) upstream of the CmeA gene.
Three resistant and ﬁve intermediate strains presented polymor-
phisms (Table 3) in these regions: six strains had a modiﬁed IR,
either a T-48!C transition in the ﬁrst half-site of the IR or an A-
37!G or C-36!A transition in the second half-site of the IR, and
two strains exhibited single deletions.
3.2.4. Presence of the ermB gene
Four ermB-positive isolates, including two ERY-resistant strains
(cj8091 and cj8036) and two ERY-intermediate resistantisms Polymorphisms in the
IR regionc
n L22 Deletion
109T E111A T114A TTTKA (120–124) T(130) TGTAATAAATATTACA
109T E111A T114A TTTKA (120–124) T(130) TGCAATAAATATTACA
109T E111A T114A TTTKA (120–124) T(130) TGCAATAAATATTACA
105V S109T E111A T114A TTTKA (120–124) T(130) TGTAATAAAAATTATA
 - TGTAATAAATATTGCA
109T E111A T114A TTTKA (120–124) T(130) TGCAATAAATATTACA
109T E111A T114A TTTKA (120–124) T(130) TGCAATAAATATTACA
 S109A - TGTAATAAAA*TTACA
 S109A - TGTAATAAAA*TTACA
 S109A TTTKA (120–124) T(130) TGTAATAAAAATTACA
- TGTAATAAAAATTACA
Ser; I, Ile; G, Gly; T, Thr; E, Glu; Q, Gln; R, Arg; K, Lys; wt, wild-type.
accession number NC_002163).
J. Zhou et al. / International Journal of Infectious Diseases 42 (2016) 28–33 31strains (cj94473 and cj6033), were detected in this study. To
further identify the length of the ermB gene, the whole fragment
was ampliﬁed using Cjerm-F (50-GAGTGTGTTGATAGTGCAGTATC-
30) and Cjerm-R (50-GTAACGTGTAACTTTCCAAATTTAC-30) primers
designed on the basis of GenBank accession number KC575115.
1. The ermB gene in these four isolates contained 738 base pairs.
4. Discussion
Campylobacter jejuni has been one of the leading causes of
gastrointestinal illness in humans in recent years.19 Although a
rapid increase in the proportion of antimicrobial agent-resistant C.
jejuni isolated from diarrhea patients has been reported recently in
other countries,6,19,20 similar increases in antibiotic resistance
rates in clinical C. jejuni isolates have rarely been reported in China.
In the present study, the proportion of quinolone-resistant isolates
was found to have increased markedly over a period of 17 years
and reached 93.7–100% after 2000. Previous studies in other
developing countries, such as India, have reported similar results
(97%; 2008–2010).20 Fluoroquinolones are ﬁrst-line antibiotics for
acute diarrhea that can easily be purchased without a prescription,
and the overuse of ﬂuoroquinolones is thought to be the main
underlying cause of the trends described above. Additionally, the
increasing level of ﬂuoroquinolone-resistant isolates might be
attributed to the widespread use of quinolones in the food animal
industry, especially in poultry production in China.8,21
Similar to quinolones, an increase in tetracycline (TET/DOX)
resistance in C. jejuni was also found in the present study. These
data are consistent with those from previous studies on tetracy-
cline-resistant C. jejuni isolated from non-clinical samples in other
regions.21–24 However, the tetracycline resistance rates of clinical
isolates from diarrheal patients in several studies have been
distinctly lower than those observed in the present study.20,25,26 In
China, tetracyclines are also commonly used to treat and prevent
bacterial diseases in poultry and have rarely been used to treat
human campylobacteriosis over the past two decades.23 Hence, it
is suspected that the food-borne transmission of tetracycline-
resistant strains to humans might be the dominant cause of the
high prevalence of resistance to this antibiotic in C. jejuni.
With phenicols (FFC/CHL) and aminoglycosides (GEN), the
resistance rates of C. jejuni to these two classes of drugs were found
to be relatively low, but they have been rising signiﬁcantly. In
general, phenicol and aminoglycoside resistance has been docu-
mented as being of low occurrence among C. jejuni strains.1,27,28
CHL and GEN are used minimally in the treatment of human
diarrhea due to their adverse effects, and ﬂorfenicol has been
added to animal feed as a growth promoter.21,29 Therefore, the high
prevalence of resistance to these antibiotics in China might be due
to their overuse in food-producing animals.23
In this study, the majority of the C. jejuni strains had multiple
resistance to combined quinolones and tetracyclines, and the
prevalence of isolates that were resistant to the combination of
these two antibiotics and phenicols increased strikingly from
1994 to 2010. Few reports have observed such high frequencies of
multidrug resistance in clinical C. jejuni isolates. The multidrug
resistance patterns and the high MICs of these antibiotics restrict
the options for suitable antimicrobial agents for use against human
campylobacteriosis, making empirical treatment more difﬁcult. It
is noteworthy that the ratios of resistant strains for almost all of the
aforementioned antibiotics improved signiﬁcantly after 2000
(see Table 2). Nevertheless, it was not possible to ﬁnd direct
evidence for the signiﬁcantly increasing resistant strains in China
after 2000 in the literature. It is of note that along with
the economic development in China, animal husbandry has
grown rapidly since the beginning of the 21st century, and a
number of antibiotics, such as ﬂuoroquinolones, tetracyclines,aminoglycosides, and phenicols, are added routinely to animal feed
to treat and prevent bacterial diseases.23 This might be one of the
reasons for the increased antibiotic-resistant strains in China.
Further studies are necessary to explore the mechanisms of this
prevalent trend.
In this study, the rate of ERY resistance seemed to be the lowest
(4/203; 2%), and this result is similar to those of other studies.20,30–
32 These data also conﬁrm that macrolides remain the most
effective antibiotics for human campylobacteriosis in China.
Despite decades of ERY use, its resistance rate in Campylobacter
strains has remained low. Nevertheless, an increase in ERY-
resistant C. jejuni in poultry has been observed recently in China.8
Therefore, further investigation of the mechanisms underlying
resistance to macrolides is needed and may provide a basis for
monitoring the emergence of antibiotic resistance.
Target modiﬁcation (e.g., point mutations in the 23S rRNA gene
or in the ribosomal proteins) and the active efﬂux responsible for
ERY-resistant strains have been identiﬁed in Campylobacter. The
A2075G mutation in the 23S rRNA appeared to be the main
contributor to high-level ERY resistance (MIC 256 mg/ml) in C.
jejuni.15 In the present study, all of the strains resistant to ERY had
MICs 256 mg/ml, and three of the four C. jejuni strains (cj8036,
cj2000, and cj7083) exhibited the A2075G mutation. The high-
level ERY-resistant strain cj8091 carried no A2075G mutation, but
the rRNA methylase gene ermB was detected. Similar reports have
also been observed by Qin et al.18 The ermB gene represents a major
mechanism for macrolide resistance in other bacteria;33 however,
it was not identiﬁed in Campylobacter until recently. Qin et al. ﬁrst
reported the identiﬁcation of a horizontally transmitted ermB gene
that mediated high-level macrolide resistance in a single
Campylobacter coli isolated from a farm animal.18 They further
analyzed the characteristics of the 58 ermB-positive Campylobac-
ter isolates, and the presence of both the 23S rRNA mutation and
ermB gene did not appear to exert an additive effect on resistance,
indicating that macrolide-resistant isolates harboring both mech-
anisms do not differ signiﬁcantly from ermB alone with regard to
antibiotic resistance.34 Compared with cj08091, the macrolide MIC
of cj8036, which harbors both the A2075G mutation and the ermB
gene, did not exceed 512 mg/ml, the result of which is consistent
with the above report.34 Thus, the detailed mechanisms by which
ermB is involved in macrolide resistance in combination with the
A2075G mutation warrant further investigation. Surprisingly, the
ermB gene was also observed in two intermediate strains (cj94473
and cj6033) and the earliest ermB-positive strain cj94473, which
was derived in 1994. This ermB-positive strain was isolated far
earlier than in previous reports in which most of the isolates
harboring ermB with identical high-level MICs against macrolide
were derived between 2011 and 2012.34 Notably, the ermB-
positive isolates typically exhibited resistance to multiple classes
of antibiotics irrespective of the location of ermB (i.e., on a plasmid
or the chromosome).18,34,35 Although the authors are not aware of
the location of ermB in the strains observed in the present study,
multidrug resistance similar to that reported in previous studies
was observed in this study (data not shown).
L4 and L22 are highly conserved proteins among bacteria due to
their functions in ribosomes. Mutations in the large loop of the L4
protein (residues 55 to 77) and the L22 protein (residues 78 to 98)
have been conﬁrmed to be associated with macrolide resistance in
various bacteria. In the present study, no variations were found in
loop regions of the L4 or L22 proteins (Table 3). Most importantly,
these mutations have also been identiﬁed in susceptible isolates in
previous reports.36–38 In L22, amino acid deletions or insertions
seemed to be more important than substitutions.39 In the present
study, however, the delThr–Thr–Thr–Lys–Ala at positions 120–124
and delThr at position 130 were observed in L22 in both the
susceptible and resistant strains. These insertions likely do not
J. Zhou et al. / International Journal of Infectious Diseases 42 (2016) 28–3332affect the entry of macrolides to the ribosome. These observations
suggest that the mutations in L4 and L22 were unlikely to directly
contribute to ERY resistance in the isolates.
CmeR is a transcriptional repressor that modulates the
expression of the efﬂux pump CmeABC operon by binding
speciﬁcally with a CmeR–CmeA intergenic region upstream of
the CmeA gene in C. jejuni.40 Single-nucleotide deletions and
transitions in the IR region have been associated with the
overproduction of the CmeABC and contribute to macrolide
resistance.40–42 In this study, the T-48!C transition was found
in two resistant (cj8036 and cj2000) and two intermediate strains
(cj6033 and cj2260) in which mutations have also been observed
previously.42 Therefore, the misregulation of the CmeABC operon
can be expected in these strains. Moreover, the interplay between
CmeABC and the mutations in the 23S rRNA may have resulted in
high-level ERY resistance in the strains observed in the present
study.38,43 Other mutations, such asD-41A and A-37!G transi-
tions in the second half-site of the IR, were detected in
intermediate strains. To the authors’ knowledge, this is the ﬁrst
report of these mutations in clinical isolates. It is speculated that
these mutations would theoretically prevent the binding of the
half-sites and consequently deregulate the expression of the
CmeABC operon. Recent studies have described mutations of CemR,
CosR, and other efﬂux system genes such as CmeDEF that have also
been deemed to be involved in the occurrence of macrolide
resistance in C. jejuni.44–46 Therefore, the speciﬁc mechanisms of
the contribution of efﬂux systems to ERY resistance remain
unclear, and additional studies are needed. Overall, these results
indicated that CmeABC might have contributed to the macrolide
resistance in the C. jejuni strains investigated in this study.
In summary, this is the ﬁrst comprehensive study on the recent
trend of antimicrobial resistance and the molecular mechanisms of
macrolide resistance in clinical C. jejuni strains isolated in China.
This study suggests that further application of the aforementioned
antibiotics should be restricted in human and veterinary practice
due to the presence of high percentages of resistant strains
resulting from these antibiotics.
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